A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Recruiting

Phase 1

HFB200301 & TislelizumabA Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Sponsor:

HiFiBiO Therapeutics

Code:

NCT05238883

Conditions

Gastric Cancer

Renal Cell Carcinoma

Melanoma

Sarcoma

Testicular Germ Cell Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

HFB200301

Tislelizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-12. This information was provided to ClinicalTrials.gov by HiFiBiO Therapeutics on 2025-04-11.